Deep vein thrombosis and pulmonary embolism management in ICU

Also known as DVT · PE management · Venous thromboembolism treatment · Massive PE · Submassive PE · Catheter-directed thrombolysis

ICU management of venous thromboembolism (VTE) — DVT and PE. Severity stratification of PE: (1) MASSIVE (high-risk): sustained hypotension (SBP <90) or shock → thrombolysis or embolectomy. (2) SUBMASSIVE (intermediate-risk): RV dysfunction + biomarker elevation, normotensive → monitor closely, consider rescue thrombolysis. (3) LOW-RISK (minor): normal RV, normal biomarkers → anticoagulation, possible early discharge. Anticoagulation: DOACs (rivaroxaban, apixaban) first-line for stable; LMWH/heparin for unstable or renal failure; warfarin for long-term if antiphospholipid syndrome. Thrombolysis: alteplase 100 mg over 2 h (massive PE); a 50 mg tenecteplase bolus has been reported in arrest. Catheter-directed thrombolysis: low-dose alteplase, emerging. Surgical embolectomy: if thrombolysis contraindicated.

high38 referencesUpdated 20 Aug 202620 min readSource-verified · Sept 2026

Checked against its sources on 11 Sept 2026

Practise this topic

8 MCQs

The one-line ICU answer

VTE management turns on one decision — stratify the PE by early-mortality risk, then let the strata drive the intensity. Massive (high-risk) PE (shock or sustained hypotension) carries 25 per cent in-hospital mortality in cardiogenic shock and 65 per cent when CPR is needed, and gets reperfusion now — alteplase 100 mg over 2 h, or surgical or percutaneous embolectomy if lysis is contraindicated. Submassive (intermediate-risk) PE is normotensive with RV dysfunction plus troponin elevation — anticoagulate and monitor in ICU, hold rescue thrombolysis in reserve (PEITHO: routine lysis trades bleeding and stroke for no mortality benefit). Low-risk PE (sPESI 0, normal RV, normal biomarkers) gets anticoagulation and may go home. DOACs (rivaroxaban, apixaban) are first-line for the stable patient; LMWH or UFH for the unstable or renally impaired; warfarin for antiphospholipid syndrome.^[25]^[2]^[4]^[1]

Meet the patient

A 58-year-old man, three weeks out from a right total hip replacement, presents with sudden pleuritic chest pain and dyspnoea — diaphoretic, confused, GCS 14, SBP 76, HR 132, RR 32, SpO2 88 per cent on 15 L. His JVP is elevated, the lung fields clear. The ECG shows sinus tachycardia with an S1Q3T3 pattern and T-wave inversion across V1 to V4. Bedside echo: a dilated RV (RV-to-LV ratio 1.2), the McConnell sign, septal flattening, TAPSE 12 mm, a plethoric IVC. CTPA confirms a saddle embolus.^[1]

The whole topic turns on where this patient sits on the severity ladder — and he sits at the top. The question that decides his first hour is haemodynamic: crashing or not. The cuff answers in seconds, the echo confirms RV strain in a minute, and the answer — high-risk PE — sends you to the thrombolysis, not the scanner: in the Kasper registry of major PE, unstable patients were lysed on bedside echo findings without further diagnostic studies.^[25]

References38Show

[1]Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J, 2020.PMID 31504429
[2]Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med, 2002.PMID 12374874
[4]Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med, 2014.PMID 24716681
[5]Said A, Sahlieh A, Sayed L A comparative analysis of the efficacy and safety of therapeutic interventions in phlegmasia cerulea dolens. Phlebology, 2021.PMID 33236674
[6]Bates SM Pulmonary Embolism in Pregnancy. Semin Respir Crit Care Med, 2021.PMID 33548928
[7]PIOPED Investigators Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED) JAMA, 1990.PMID 2332918
[8]Wells PS, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer Thromb Haemost, 2000.PMID 10744147
[9]van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography JAMA, 2006.PMID 16403929
[10]Aujesky D, et al. A prediction rule to identify low-risk patients with pulmonary embolism Arch Intern Med, 2006.PMID 16432084
[11]Kline JA, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria J Thromb Haemost, 2008.PMID 18318689
[12]Rudski LG, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography J Am Soc Echocardiogr, 2010.PMID 20620859
[13]Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med, 2009.PMID 19966341
[14]Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med, 2012.PMID 22449293
[15]Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med, 2013.PMID 23991658
[16]Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study JAMA, 2014.PMID 24643601
[17]Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism Circulation, 2014.PMID 24226805
[18]Piazza G, Hohlfelder B, Jaff MR, et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study JACC Cardiovasc Interv, 2015.PMID 26315743
[19]Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group N Engl J Med, 1998.PMID 9459643
[20]Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial JAMA, 2015.PMID 25919526
[21]van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study Lancet, 2017.PMID 28549662
[22]Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis N Engl J Med, 2017.PMID 29211671
[23]Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report Chest, 2016.PMID 26867832
[24]Dobler CC Overdiagnosis of pulmonary embolism: definition, causes and implications Breathe (Sheff), 2019.PMID 30838059
[25]Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol, 1997.PMID 9350909
[26]Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med, 1993.PMID 8214998
[27]Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv, 2018.PMID 30482768
[28]Perrott J, Henneberry RJ, Zed PJ Thrombolytics for cardiac arrest: case report and systematic review of controlled trials. Ann Pharmacother, 2010.PMID 21119096
[29]Simcox LE, Ormesher L, Tower C, Greer IA Pulmonary thrombo-embolism in pregnancy: diagnosis and management. Breathe (Sheff), 2015.PMID 27066121
[30]Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018.PMID 30002145
[31]Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013.PMID 23808982
[32]Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med, 2020.PMID 32223112
[33]Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol, 2018.PMID 29746227
[34]McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol, 1996.PMID 8752195
[35]Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA, 2015.PMID 26284719
[36]Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med, 2017.PMID 28316279
[37]Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013.PMID 23216615
[38]Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012.PMID 23121403
[39]Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012.PMID 22621626